On September 7, 2022 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022 (Press release, Oncternal Therapeutics, SEP 7, 2022, View Source [SID1234619152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer, will present a corporate overview, which will be available on demand, starting on Monday, September 12th at 7:00am (ET), and the Company will be available for one-on-one meetings.

The webcast will be available online at investor.oncternal.com for up to 30 days.